Global C-Reactive Protein Testing Market

Global C-Reactive Protein Testing Market Size Insights Forecasts to 2035

• The Global C-Reactive Protein Testing Market Size Was Estimated at USD 2.75 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.17% from 2025 to 2035
• The Worldwide C-Reactive Protein Testing Market Size is Expected to Reach USD 5.89 Billion by 2035
• Europe is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Decisions Advisors and Consulting, The Global C-Reactive Protein Testing Market Size was worth around USD 2.75 Billion in 2024 and is predicted to Grow to around USD 5.89 Billion by 2035 with a compound annual growth rate (CAGR) of 7.17% from 2025 to 2035. Increased prevalence of chronic diseases and growing need for CRP testing to diagnose and manage these conditions are contributing factors to the growth of the market for CRPs. As the demand for precision medicine increases, so does the need for CRP testing. C-reactive protein (CRP) is considered an acute-phase reactant, with increased levels noted in early disease states as a precursor to the inflammatory response of the body.

 

Market Overview

The global C-reactive protein (CRP) testing market refers to the worldwide industry focused on diagnostic tests that measure levels of C-reactive protein in the blood. CRP is an acute-phase protein produced by the liver in response to inflammation, infection, or tissue injury. Elevated CRP levels are used as a biomarker to detect and monitor conditions such as cardiovascular disease, diabetes, rheumatoid arthritis, lupus, cancer, and other inflammatory disorders. Testing for C, C-reactive protein (CRP) evaluates the amount of C, C-reactive protein that the liver produces when there is inflammation. Various stimuli like infections, autoimmune diseases, and atherosclerosis may cause either acute or chronic inflammation, and the resulting high levels of CRP can be used as an indicator. The test is helpful in the identification and monitoring of inflammatory diseases, deciding the severity of infections, and determining the risk of heart diseases. It is instrumental in estimating the likelihood of a person having a heart attack and stroke.

 

Report Coverage

This research report categorises the C-reactive protein testing market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the C-reactive protein testing market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the C-reactive protein testing market.      

 

Driving Factors  

The C-reactive protein testing market is currently undergoing pretty major changes, largely due to an increased awareness of chronic diseases and the importance of early diagnosis. Healthcare professionals have been warming up to the idea that c, C-reactive protein (CRP) can serve as an effective biomarker for inflammation that is linked to several diseases, such as cardiovascular diseases, and accounts for autoimmune disorders. Hence, this increased awareness is going to considerably raise the demand for CRP tests, which provide crucial information about the health state of the patient. Besides that, the market for C, C-Reactive Protein Testing is also witnessing new technological innovations, which in turn result in more accessible and convenient testing for patients and healthcare providers. Lifestyle-related diseases are surfacing more and more frequently, thus regular monitoring of inflammatory markers becomes necessary. As the global population keeps getting older and chronic illnesses become the norm rather than the exception, healthcare systems require more effective diagnostic tools.

 

Restraining Factors  

C-reactive protein is a non-specific indicator of inflammation. Therefore, this test does not help in the precise diagnosis of any disease. So, the limitation of it being a non, self, sufficient diagnostic test may hinder the growth of this market. Moreover, various diagnostic tests are widely available for the accurate diagnosis of a specific disease. As an example, high-accuracy tests like coronary CT angiography, electrocardiography (ECG or EKG), exercise cardiac stress test, etc., are available for the screening of cardiovascular diseases.

 

Market Segmentation    

The C-reactive protein testing market share is classified into assay type, detection range, and disease.     

• The immunoturbidimetric assays segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR over the forecast period.        

Based on the assay type, the C-reactive protein testing market is differentiated into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assays, and others. Among these, the immunoturbidimetric assays segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR over the forecast period. This process's dominant position is greatly boosted by its implementation in chronic respiratory and cardiac disorders. Immunoturbidimetric assay technological developments will drive market expansion due to provide quick and accurate CRP testing. Researchers around the world are creating cutting-edge and creative assays.

 

• The HS-CRP segment accounted for the highest revenue share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the detection range, the C-reactive protein testing market is divided into conventional CRP and HS-CRP. Among these, the HS-CRP segment accounted for the highest revenue share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. This is due to CRP technology developments. Hs-CRP testing is more sensitive than conventional CRP testing and can identify even slight elevations in the body's CRP levels. This increases the demand for this segment by making it useful in determining the risk of coronary artery disease. Additionally, a variety of hs-CRP-based point-of-care (POC) testing equipment is being developed by various market entities, which is contributing to the market's growth.

 

• The rheumatoid arthritis segment accounted for the highest market revenue in 2024 and is projected to grow at a remarkable CAGR over the forecast period.     

Based on the disease, the C-reactive protein testing market is segmented into diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. Among these, the rheumatoid arthritis segment accounted for the highest market revenue in 2024 and is projected to grow at a remarkable CAGR over the forecast period. This is due to the improved diagnostic skills. Besides, medical professionals search for efficient monitoring and treatment methods; the recognition and validation of CRP testing as a trustworthy indicator for arthritic disorders drives this market.

 

 

Regional Segment Analysis of the C-Reactive Protein Testing Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the C-reactive protein testing market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the C-reactive protein testing market over the predicted timeframe. The main reasons for that are a steadily growing population and a growing elderly population in countries such as Japan and China. Moreover, the hospitals in the region are adopting CRP testing, and malaria and cardiovascular diseases are becoming more widespread. Besides that, the major players are undertaking more and more strategic initiatives that are aimed at broadening their product portfolios, and the population is becoming more aware. These are just some of the factors that can help the regional market to grow.

 

In November 2022, LumiraDx launched a C-reactive Protein (CRP) point-of-care test in India to help combat antimicrobial resistance (AMR). The test enables clinicians to quickly distinguish between bacterial and viral infections, reducing unnecessary antibiotic prescriptions.

 

Europe is expected to grow at a rapid CAGR in the C-reactive protein testing market during the forecast period. The C-reactive protein testing market in Europe is a large market, with Germany, France, and the UK being the leading countries. The European region, for example, has more than 1.9 million deaths and 3.7 million new cancer cases each year. The market is also driven by the increasing incidence of cardiovascular diseases, along with preventive healthcare getting more attention from the public at large. Major factors impelling the growth of the market include increasing prevalence of cardiovascular diseases, advancements in testing methodologies, Point, of, Care testing expansion, and supportive reimbursement policies.

 

Germany C, the reactive Protein testing market has witnessed significant advancements recently. High, sensitivity CRP assays and point, of, care testing devices are among the technological advancements that have been developed.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organizations/companies involved within the C-reactive protein testing market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• Abaxis, Inc.
• Abbott, Danaher
• Aidian
• BODITECH MED, INC.
• F. Getein Biotech, Inc.
• Hoffmann-La Roche Ltd.
• HORIBA, Ltd., Inc.
• Merck KGaA
• Ortho Clinical Diagnostics
• Quest Diagnostics
• Randox Laboratories Ltd.
• Roche Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the C-reactive protein testing market based on the below-mentioned segments: 

 

Global C-Reactive Protein Testing Market, By Assay Type

• Enzyme-linked Immunosorbent Assay (ELISA)
• Chemiluminescence Immunoassay (CLIA)
• Immunoturbidimetric Assays
• Others

 

Global C-Reactive Protein Testing Market, By Detection Range

• Conventional CRP
• HS-CRP

 

Global C-Reactive Protein Testing Market, By Disease

• Diabetes
• Rheumatoid Arthritis
• Cardiovascular Disease
• Inflammatory Bowel Disease
• Others

 

Global C-Reactive Protein Testing Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the current size of the global C-Reactive Protein Testing Market?

The market was valued at USD 2.75 billion in 2024.

 

2. What is the projected market size by 2035?

It is expected to reach USD 5.89 billion by 2035.

 

3. What is the CAGR for the forecast period?

The market is projected to grow at a CAGR of 7.17% from 2025 to 2035.

 

4. Which assay type leads the market?

Immunoturbidimetric assays dominated in 2024 and are expected to grow substantially.

 

5. What is the top detection range segment?

HS-CRP held the highest revenue share in 2024 due to its sensitivity for cardiovascular risk assessment.

 

6. Which disease segment has the highest revenue?

Rheumatoid arthritis accounted for the largest share in 2024.

 

7. Which region holds the largest market share?

Asia-Pacific is anticipated to have the largest share, driven by population growth and disease prevalence.

 

8. What drives market growth?

Rising chronic diseases, early diagnosis needs, technological advancements, and ageing populations fuel expansion.